These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. Liew F; Talwar S; Cross A; Willett BJ; Scott S; Logan N; Siggins MK; Swieboda D; Sidhu JK; Efstathiou C; Moore SC; Davis C; Mohamed N; Nunag J; King C; Thompson AAR; Rowland-Jones SL; Docherty AB; Chalmers JD; Ho LP; Horsley A; Raman B; Poinasamy K; Marks M; Kon OM; Howard L; Wootton DG; Dunachie S; Quint JK; Evans RA; Wain LV; Fontanella S; de Silva TI; Ho A; Harrison E; Baillie JK; Semple MG; Brightling C; Thwaites RS; Turtle L; Openshaw PJM; ; EBioMedicine; 2023 Jan; 87():104402. PubMed ID: 36543718 [TBL] [Abstract][Full Text] [Related]
4. Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines. Epsi NJ; Richard SA; Lindholm DA; Mende K; Ganesan A; Huprikar N; Lalani T; Fries AC; Maves RC; Colombo RE; Larson DT; Smith A; Chi SW; Maldonado CJ; Ewers EC; Jones MU; Berjohn CM; Libraty DH; Edwards MS; English C; Rozman JS; Mody RM; Colombo CJ; Samuels EC; Nwachukwu P; Tso MS; Scher AI; Byrne C; Rusiecki J; Simons MP; Tribble D; Broder CC; Agan BK; Burgess TH; Laing ED; Pollett SD; Clin Infect Dis; 2023 Feb; 76(3):e439-e449. PubMed ID: 35608504 [TBL] [Abstract][Full Text] [Related]
5. Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV. Verburgh ML; van Pul L; Grobben M; Boyd A; Wit FWNM; van Nuenen AC; van Dort KA; Tejjani K; van Rijswijk J; Bakker M; van der Hoek L; Schim van der Loeff MF; van der Valk M; van Gils MJ; Kootstra NA; Reiss P Microbiol Spectr; 2023 Jun; 11(3):e0115523. PubMed ID: 37166335 [TBL] [Abstract][Full Text] [Related]
6. A Single Dose of BNT162b2 Messenger RNA Vaccine Induces Airway Immunity in Severe Acute Respiratory Syndrome Coronavirus 2 Naive and Recovered Coronavirus Disease 2019 Subjects. Martinuzzi E; Benzaquen J; Guerin O; Leroy S; Simon T; Ilie M; Hofman V; Allegra M; Tanga V; Michel E; Boutros J; Maniel C; Sicard A; Glaichenhaus N; Czerkinsky C; Blancou P; Hofman P; Marquette CH Clin Infect Dis; 2022 Dec; 75(12):2053-2059. PubMed ID: 35579991 [TBL] [Abstract][Full Text] [Related]
7. Salivary and serum IgA and IgG responses to SARS-CoV-2-spike protein following SARS-CoV-2 infection and after immunization with COVID-19 vaccines. Li D; Calderone R; Nsouli TM; Reznikov E; Bellanti JA Allergy Asthma Proc; 2022 Sep; 43(5):419-430. PubMed ID: 36065108 [No Abstract] [Full Text] [Related]
8. Understanding antibody magnitude and durability following vaccination against SARS-CoV-2. Murphy QM; Lewis GK; Sajadi MM; Forde JE; Ciupe SM Math Biosci; 2024 Oct; 376():109274. PubMed ID: 39218212 [TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response. Takamatsu Y; Omata K; Shimizu Y; Kinoshita-Iwamoto N; Terada M; Suzuki T; Morioka S; Uemura Y; Ohmagari N; Maeda K; Mitsuya H Microbiol Spectr; 2022 Dec; 10(6):e0271622. PubMed ID: 36219096 [TBL] [Abstract][Full Text] [Related]
10. Decline of humoral immune responses after natural SARS-CoV-2 infection can be efficiently reversed by vaccination. Oktelik FB; Yilmaz V; Gelmez MY; Akdeniz N; Pamukcu C; Sutlu T; Kose M; Tuzun E; Deniz G Can J Microbiol; 2022 Aug; 68(8):543-550. PubMed ID: 35852365 [TBL] [Abstract][Full Text] [Related]
11. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity. Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735 [TBL] [Abstract][Full Text] [Related]
12. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19? Scaggs Huang F J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545 [TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune responses. Puhach O; Bellon M; Adea K; Bekliz M; Hosszu-Fellous K; Sattonnet P; Hulo N; Kaiser L; Eckerle I; Meyer B EBioMedicine; 2023 Dec; 98():104893. PubMed ID: 38035462 [TBL] [Abstract][Full Text] [Related]
14. Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination. Graninger M; Camp JV; Aberle SW; Traugott MT; Hoepler W; Puchhammer-Stöckl E; Weseslindtner L; Zoufaly A; Aberle JH; Stiasny K Front Immunol; 2022; 13():888794. PubMed ID: 35711424 [TBL] [Abstract][Full Text] [Related]
15. The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines. Chan RWY; Liu S; Cheung JY; Tsun JGS; Chan KC; Chan KYY; Fung GPG; Li AM; Lam HS Front Immunol; 2021; 12():744887. PubMed ID: 34712232 [TBL] [Abstract][Full Text] [Related]
16. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J Front Immunol; 2021; 12():802858. PubMed ID: 35003131 [TBL] [Abstract][Full Text] [Related]
17. Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections. Egri N; Calderón H; Martinez R; Vazquez M; Gómez-Caverzaschi V; Pascal M; Araújo O; Juan M; González-Navarro EA; Hernández-Rodríguez J Front Immunol; 2023; 14():1146841. PubMed ID: 37180097 [TBL] [Abstract][Full Text] [Related]
18. Early humoral and cellular responses after bivalent SARS-CoV-2 mRNA-1273.214 vaccination in long-term care and retirement home residents in Ontario, Canada: An observational cohort study. Breznik JA; Rahim A; Bhakta H; Clare R; Zhang A; Ang J; Stacey HD; Liu LM; Kennedy A; Bilaver L; Hagerman M; Kajaks T; Bramson JL; Nazy I; Miller MS; Costa AP; Bowdish DME; J Med Virol; 2023 Oct; 95(10):e29170. PubMed ID: 37822054 [TBL] [Abstract][Full Text] [Related]
19. Comparison of Levels of Nasal, Salivary, and Plasma Antibody to Severe Acute Respiratory Syndrome Coronavirus 2 During Natural Infection and After Vaccination. Cohen JI; Dropulic L; Wang K; Gangler K; Morgan K; Liepshutz K; Krogmann T; Ali MA; Qin J; Wang J; Vogel JS; Lei Y; Suzuki-Williams LP; Spalding C; Palmore TN; Burbelo PD Clin Infect Dis; 2023 Apr; 76(8):1391-1399. PubMed ID: 36482505 [TBL] [Abstract][Full Text] [Related]
20. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. Cervia C; Nilsson J; Zurbuchen Y; Valaperti A; Schreiner J; Wolfensberger A; Raeber ME; Adamo S; Weigang S; Emmenegger M; Hasler S; Bosshard PP; De Cecco E; Bächli E; Rudiger A; Stüssi-Helbling M; Huber LC; Zinkernagel AS; Schaer DJ; Aguzzi A; Kochs G; Held U; Probst-Müller E; Rampini SK; Boyman O J Allergy Clin Immunol; 2021 Feb; 147(2):545-557.e9. PubMed ID: 33221383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]